<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Triamcinolone (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Triamcinolone (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Triamcinolone (nasal): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12327" href="/d/html/12327.html" rel="external">see "Triamcinolone (nasal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16060" href="/d/html/16060.html" rel="external">see "Triamcinolone (nasal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9606519"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nasacort Allergy 24HR Children [OTC] [DSC];</li>
<li>Nasacort Allergy 24HR [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870661"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Triamcinolone AQ;</li>
<li>Nasacort AQ</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9608610"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Nasal</li></ul></div>
<div class="block doa drugH1Div" id="F9606717"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note:</b> For patients with mucous crusting, rinsing with saline nasal spray before triamcinolone administration can remove mucous crusting and improve nasal coating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.1'])">Ref</a></span>). If nasal obstruction is so severe that sprays cannot penetrate, consider concomitant use of an intranasal decongestant for up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1997443-038e-4e3a-bb51-889a4f16311b">Acute bacterial rhinosinusitis, adjunct to antibiotics</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute bacterial rhinosinusitis, adjunct to antibiotics (empiric treatment) (off-label use): </b>
<b>Note</b>: Dosing recommendations based on general dosing range in manufacturer's labeling. <b>Intranasal:</b> Two sprays (110 mcg) in each nostril once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>A</b>
<b>llergic r</b>
<b>hinitis</b>
<b>:</b>
<b> Intranasal:</b> Two sprays (110 mcg) in each nostril once daily; once symptoms are controlled, reduce to 1 spray (55 mcg) in each nostril once daily (maximum: 2 sprays [110 mcg] in each nostril once daily). Discontinue therapy if adequate symptomatic relief is not observed within 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25644617','lexi-content-ref-30879006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25644617','lexi-content-ref-30879006'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>N</b>
<b>onallergic r</b>
<b>hinitis </b>
<b>(off-label use): Intranasal:</b> 2 sprays (110 mcg) in each nostril once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lieberman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lieberman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99e6d7cb-82d2-459d-a28d-ef4733dc10bf">Rhinosinusitis, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, c</b>
<b>hronic (off-label use): Note</b>: Dosing recommendations based on general dosing range in manufacturer's labeling. <b>Intranasal:</b> Two sprays (110 mcg) in each nostril once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f19228ca-0b9f-4938-821a-f482214139a6">Upper respiratory allergies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory allergies (OTC):</b>
<b>Intranasal:</b> Two sprays (110 mcg) in each nostril once daily; once symptoms are controlled, reduce to 1 spray (55 mcg) in each nostril once daily (maximum: 2 sprays [110 mcg] in each nostril once daily). Discontinue therapy if adequate symptomatic relief is not observed within 1 week.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991475"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988817"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F9606718"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9606716"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16060" href="/d/html/16060.html" rel="external">see "Triamcinolone (nasal): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic r</b>
<b>hinitis (seasonal and perennial):</b> Discontinue treatment and contact health care provider if adequate control of symptoms has not occurred after 3 weeks of use (1 week if OTC use): Intranasal: 55 mcg/spray:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: One spray <b>per nostril</b> once daily. (Total daily dose 110 mcg/day). Maximum daily dose: 1 spray <b>per nostril</b>/day (110 mcg/day)</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Initial: One spray <b>per nostril</b> once daily (Total daily dose: 110 mcg/day); may increase to 2 sprays <b>per nostril</b> once daily if response not adequate (Total daily dose 220 mcg/day); once symptoms are controlled, reduce to 1 spray <b>per nostril</b> once daily (Total daily dose 110 mcg/day). Maximum daily dose: 2 sprays <b>per nostril</b>/day (220 mcg/day)</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Initial: Two sprays <b>per nostril</b> once daily (Total daily dose: 220 mcg/day); once symptoms are controlled, reduce dose to 1 spray <b>per nostril</b> once daily (total daily dose: 110 mcg/day). Maximum daily dose: 2 sprays <b>per nostril</b>/day (220 mcg/day)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192999"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51193000"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F9606590"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">Reported adverse reactions are for children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (Weinstein 2009), skin rash (Weinstein 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (Bernstein 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (Weinstein 2009), nausea (Gross 2002), oral candidiasis (Settipane 1995), upper abdominal pain (Weinstein 2009), vomiting (Weinstein 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (nasal) (Chang 2013), viral infection (Weinstein 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (including application-site pain, blood in nasal mucosa, burning sensation of the nose, epistaxis, nasal mucosa irritation, sneezing, and stinging sensation of the nose) (Berger 2003; Gross 2002; Karaulov 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Bitter taste (Baccioglu Kavut 2012), headache (Gross 2002), insomnia (Gross 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinopathy (central serous chorioretinopathy) (Nakatsuka 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (Weinstein 2009), cough (Weinstein 2009), dry nose (Gross 2002), nasal cavity pain (Chang 2013), nasal discomfort (Karaulov 2019), nasopharyngitis (Weinstein 2009), pharyngitis (Gross 2002), pharyngolaryngeal pain (Weinstein 2009), rhinitis (Gross 2002), sinusitis (Weinstein 2009), upper respiratory tract infection (Bernstein 1996)</p></div>
<div class="block coi drugH1Div" id="F9606570"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to triamcinolone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use in children &lt;2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Tuberculosis (TB) disease or infection (active or latent TB), or untreated fungal, bacterial, and viral infection.</p></div>
<div class="block war drugH1Div" id="F9606571"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: When used at excessive doses, may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and/or measles should be avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Use caution or avoid in patients with ocular herpes simplex, tuberculosis (TB) infection (latent TB), and/or TB reactivity, or in patients with untreated fungal, viral, or bacterial infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Consult a health care provider before use if you have had recent nose ulcers or nose surgery; have a nose injury that has not healed; or are using a steroid for asthma, allergies or skin rash. Discontinue use and consult a health care provider if symptoms do not improve after 1 week, or if infection (eg, persistent fever), changes in vision, or frequent nosebleeds occur. Do not use for the common cold.</p></div>
<div class="block dosfc drugH1Div" id="F21005922"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Nasacort Allergy 24HR 10.8 mL bottles contain 60 sprays, and the 16.9 mL bottles contain 120 sprays.</p></div>
<div class="block foc drugH1Div" id="F9606843"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol, Nasal, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasacort Allergy 24HR: 55 mcg/actuation (6.8 mL, 10.8 mL, 16.9 mL) [alcohol free; contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasacort Allergy 24HR Children: 55 mcg/actuation (10.8 mL [DSC]) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 55 mcg/actuation (16.9 mL)</p></div>
<div class="block geq drugH1Div" id="F9606563"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9606845"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Nasacort Allergy 24HR Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">55 mcg/ACT (per mL): $1.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Triamcinolone Acetonide Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">55 mcg/ACT (per mL): $1.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870662"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol, Nasal, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasacort AQ: 55 mcg/actuation (16.5 g) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 55 mcg/actuation (1 ea)</p></div>
<div class="block adm drugH1Div" id="F9606775"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Shake well prior to use. Gently blow nose to clear nostrils. Avoid spraying into mouth or eyes and do <b>not</b> blow nose for 15 minutes after use.  Prime prior to first use by shaking contents well and releasing 5 sprays into the air. If product is not used for more than 2 weeks, reprime with 1 spray. Consider use of a nasal vasoconstrictor for 2 to 3 days before initiating therapy in patients with excessive nasal mucous secretion or nasal mucosa edema.</p></div>
<div class="block admp drugH1Div" id="F52614421"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intranasal use only. Shake container well before each use. Before first use, prime by releasing 5 sprays into the air away from the face. Repeat priming with 1 spray if ≥14 days between use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid blowing nose for 15 minutes after use. Do not spray into eyes or mouth. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p></div>
<div class="block use drugH1Div" id="F9606564"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis (Nasacort AQ [Canadian product]):</b> Management of seasonal and perennial allergic rhinitis in children 4 to 12 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory allergies (OTC products):</b> Relief of hay fever and other upper respiratory allergies (eg, nasal congestion, runny nose, sneezing, itchy nose) in adults and children 2 years of age and older.</p></div>
<div class="block off-label drugH1Div" id="F25488658"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute bacterial rhinosinusitis, adjunct to antibiotics (empiric treatment); Chronic rhinosinusitis; Nonallergic rhinitis</p></div>
<div class="block mst drugH1Div" id="F9606497"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nasacort may be confused with NasalCrom</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300165"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F9606624"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Triamcinolone (Nasal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Nasal).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F9606566"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of intranasal triamcinolone in pregnant women is limited (Bérard 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of intranasal corticosteroids in usual doses are generally not associated with an increased risk of fetal malformations or preterm birth (ERS/TSANZ [Middleton 2020]). However, intranasal triamcinolone has a high systemic bioavailability, and adverse fetal events have been reported. Agents other than intranasal triamcinolone may be preferred for the treatment of allergic rhinitis during pregnancy (Alhussien 2018; BSACI [Scadding 2017]).</p></div>
<div class="block mop drugH1Div" id="F23779962"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency or hypercortisolism; ocular changes, including glaucoma and cataracts; signs/symptoms of Candida infection (long-term therapy); nasal effects (eg, epistaxis, nasal discomfort, nasal septal perforation, nasal ulcerations).</p></div>
<div class="block pha drugH1Div" id="F9606677"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation</p></div>
<div class="block phk drugH1Div" id="F9606679"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Systemic absorption may occur following intranasal administration.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Biologic: 18-36 hours; Terminal (intranasal): 3.1 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~40%); feces (~60%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23669142"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Nasacort | Trialon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Respicort</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Azmacort</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Polcortolon N | Volon a</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zamacort</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Nasacort | Polcortolon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Azmacort</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Proctosteroid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Kenacort</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azmacort</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Azmacort</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zamacort</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Nasacort aq</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Nasacort</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Nasacort</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Azmacort | Kenalog | Nasacort</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nasacort AQ</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Azmacort</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Azmacor | Nasacor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29164323">
<a name="29164323"></a>Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. <i>Eur Arch Otorhinolaryngol</i>. 2018;275(2):325‐333. doi:10.1007/s00405-017-4785-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/29164323/pubmed" id="29164323" target="_blank">29164323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23031657">
<a name="23031657"></a>Baccioglu Kavut A, Kalpaklıoğlu F. Efficacy and safety of once daily triamcinolone acetonide aqueous nasal spray in adults with non-allergic and allergic rhinitis. <i>Allergol Immunopathol (Madr)</i>. 2013;41(6):374-380. doi:10.1016/j.aller.2012.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/23031657/pubmed" id="23031657" target="_blank">23031657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27045580">
<a name="27045580"></a>Bérard A, Sheehy O, Kurzinger ML, Juhaeri J. Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. <i>J Allergy Clin Immunol</i>. 2016;138(1):97-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/27045580/pubmed" id="27045580" target="_blank">27045580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12869911">
<a name="12869911"></a>Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2003;129(1):16-23. doi:10.1016/s0194-5998(03)00526-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/12869911/pubmed" id="12869911" target="_blank">12869911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8613630">
<a name="8613630"></a>Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. <i>J Allergy Clin Immunol</i>. 1996;97(3):749-755. doi:10.1016/s0091-6749(96)80151-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/8613630/pubmed" id="8613630" target="_blank">8613630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24018172">
<a name="24018172"></a>Chang GH, Wang WH. Intranasal fungal (Alternaria) infection related to nasal steroid spray. <i>Am J Otolaryngol</i>. 2013;34(6):743-745. doi:10.1016/j.amjoto.2013.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/24018172/pubmed" id="24018172" target="_blank">24018172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32077450">
<a name="32077450"></a>Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. <i>Rhinology</i>. 2020;58(suppl S29):1-464. doi:10.4193/Rhin20.600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/32077450/pubmed" id="32077450" target="_blank">32077450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12141721">
<a name="12141721"></a>Gross G, Jacobs RL, Woodworth TH, Georges GC, Lim JC. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. <i>Ann Allergy Asthma Immunol</i>. 2002;89(1):56-62. doi:10.1016/S1081-1206(10)61911-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/12141721/pubmed" id="12141721" target="_blank">12141721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26012297">
<a name="26012297"></a>Guo L, Sun X, Yang J, Liu J, Wang D. Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis. 2015;29(3):243-245, 251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/26012297/pubmed" id="26012297" target="_blank">26012297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30879006">
<a name="30879006"></a>Karaulov AV, Vylegzhanina T, Ovchinnikov A, Chernikova M, Nenasheva N. Triamcinolone acetonide versus fluticasone propionate in the treatment of perennial allergic rhinitis: a randomized, parallel-group trial. <i>Int Arch Allergy Immunol</i>. 2019;179(2):142-151. doi:10.1159/000497160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/30879006/pubmed" id="30879006" target="_blank">30879006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26800862">
<a name="26800862"></a>Lal D, Jategaonkar AA, Borish L, et al. Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. <i>Rhinology</i>. 2016;54(2):99-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/26800862/pubmed" id="26800862" target="_blank">26800862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. <i>Pediatrics</i>. 2012;130(3):576-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ task force statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31049263">
<a name="31049263"></a>Nakatsuka AS, Khanamiri HN, Lam QN, El-Annan J. Intranasal corticosteroids and central serous chorioretinopathy: a report and review of the literature. <i>Hawaii J Med Public Health</i>. 2019;78(5):151-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/31049263/pubmed" id="31049263" target="_blank">31049263</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nasacort 24 (OTC) (triamcinolone nasal) [prescribing information]. Chattanooga, TN: Chattem Inc.</div>
</li>
<li>
<div class="reference">
                  Nasacort AQ (triamcinolone acetonide spray) [product monograph]. Laval, Quebec, Canada: Sanofi Consumer Health Inc; September 2022.</div>
</li>
<li>
<div class="reference">
                  Nasacort Allergy 24HR/Nasacort AQ (triamcinolone) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Nasacort Allergy 24HR (triamcinolone) [prescribing information]. Chattanooga, TN: Chattem Inc; received January 2019.</div>
</li>
<li>
<div class="reference">
                  Nasacort Allergy 24HR Children’s (triamcinolone) [prescribing information]. Chattanooga, TN: Chattem Inc; received January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24654314">
<a name="24654314"></a>Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. <i>J Investig Allergol Clin Immunol.</i> 2013;23(7):495-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/24654314/pubmed" id="24654314" target="_blank">24654314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(suppl 2):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856‐889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1)(suppl):S1-43. doi:10.1177/0194599814561600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7614525">
<a name="7614525"></a>Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. <i>Clin Ther</i>. 1995;17(2):252-263. doi:10.1016/0149-2918(95)80023-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/7614525/pubmed" id="7614525" target="_blank">7614525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19441606">
<a name="19441606"></a>Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. <i>Ann Allergy Asthma Immunol</i>. 2009;102(4):339-347. doi:10.1016/S1081-1206(10)60340-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-nasal-drug-information/abstract-text/19441606/pubmed" id="19441606" target="_blank">19441606</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9951 Version 234.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
